Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study

Moro-Sibilot, Denis; Smit, Egbert F.; Castro, Javier de; Leśniewski-Kmak, Krzysztof; Aerts, Joachim; Villatoro, R.; Kraaij, Kees; Nacerddine, Karim; D’yachkova, Yulia; Smith, Karen; Taipale, Kaisa; Girvan, Allicia C.; Visseren‐Grul, Carla; Schnabel, Philipp A.

doi:10.1016/j.lungcan.2015.02.011

Cited by 62 publications

(52 citation statements)

References 21 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median OS of 25.5 months in our Taiwanese cohort could be the result of frequent and appropriate therapy with EGFR TKIs for patients with EGFR ‐positive status, since gefitinib was approved for first‐line therapy of EGFR ‐positive NSCLC in Taiwan in June 2011. The median OS of 16.4 and 10.8 months in Italy and Spain, respectively, were similar to earlier findings in European studies (Carrato et al., 2014; Moro‐Sibilot et al., 2015). …”

Section: Discussionmentioning

confidence: 99%

Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study

et al. 2017

View full text Add to dashboard Cite

The aim of this multinational retrospective cohort study, conducted at academic and community oncology centres, was to describe real‐world treatment patterns for patients with a confirmed diagnosis of advanced/metastatic (stage IIIB/IV) non‐small cell lung cancer (NSCLC) who initiated first‐line systemic therapy from January 2011 through June 2014. The study included 1265 patients in Italy, Spain, Germany, Australia, Korea, Taiwan and Brazil. The proportion of patients with squamous versus non‐squamous NSCLC was approximately 20% versus 75%, and associated patient demographic characteristics were similar in all countries, excepting race. Patients with squamous NSCLC were predominantly male and current/ex‐smokers. Biomarker tests were performed for the majority of patients with non‐squamous NSCLC, ranging from 54% (Brazil) to 91% in Taiwan, where, of those tested, 68% with non‐squamous NSCLC had positive epidermal growth factor receptor (EGFR)‐mutation status; in other countries the EGFR‐positive percentages ranged from 17% (Spain/Brazil) to 40% (Korea). Platinum‐based regimens were the most common first‐line therapy in all countries except Taiwan, where gefitinib was the most common first‐line agent. Median overall survival ranged from 9.3 months (Brazil) to 25.5 months (Taiwan). The diagnostic and treatment patterns recorded in this study were heterogeneous but largely in line with NSCLC guidelines during the study period.

show abstract

Section: Discussionmentioning

confidence: 99%

Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The median survival from diagnosis/relapse was 11.5 months, reflecting the survival of patients with advanced NSCLC [2], while the median survival from chest drain was 3.8 months. The relationship between p-AKT, p-S6K and p-GSK3β and survival was investigated in exploratory analyses using the Cox regression method.…”

Section: Resultsmentioning

confidence: 99%

“…In patients with advanced disease, conventional chemotherapy has reached a plateau in efficacy, with a median survival of 8-11 months [1,2]. Receptor tyrosine kinase inhibitors, such as EGFR and ALK inhibitors, can successfully treat approximately 20% of NSCLC patients [3,4], but the majority of the population have no identified clinically actionable genetic aberrations [5].…”

Section: Introductionmentioning

confidence: 99%

Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions

Puglisi

Stewart²,

Thavasu³

et al. 2016

Oncology

View full text Add to dashboard Cite

Objectives: We hypothesised that it was possible to quantify phosphorylation of important nodes in the phosphatidylinositol 3-kinase (PI3K) pathway in cancer cells isolated from pleural effusions of patients with non-small cell lung cancer (NSCLC) and study their correlation to somatic mutations and clinical outcomes. Materials and Methods: Cells were immunomagnetically separated from samples of pleural effusion in patients with NSCLC. p-AKT, p-S6K and p-GSK3β levels were quantified by ELISA; targeted next-generation sequencing was used to characterise mutations in 26 genes. Results: It was possible to quantify phosphoproteins in cells isolated from 38/43 pleural effusions. There was a significant correlation between p-AKT and p-S6K levels [r = 0.85 (95% confidence interval 0.73-0.92), p < 0.0001], but not p-AKT and p-GSK3β levels [r = 0.19 (95% confidence interval -0.16 to 0.5), p = 0.3]. A wide range of mutations was described and p-S6K was higher in samples that harboured at least one mutation compared to those that did not (p = 0.03). On multivariate analysis, p-S6K levels were significantly associated with poor survival (p < 0.01). Conclusion: Our study has shown a correlation between p-AKT levels and p-S6K, but not GSK3β, suggesting differences in regulation of the distal PI3K pathway by AKT. Higher p-S6K levels were associated with adverse survival, making it a critically important target in NSCLC.

show abstract

“…[14] In addition, a European observational study reported that pemetrexed/platinum had a median survival advantage of +2.5 months relative to taxane/platinum. [13] The consistency of the median survival estimates across studies, despite their various methodological differences and limitations, suggests that the pemetrexed/platinum survival advantage is real. Beyond that advantage, differences in costeffectiveness between NSCLC therapies will be driven largely by cost differences.…”

Section: J U S T a C C E P T E Dmentioning

confidence: 99%

“…[10,11] Another two recent studies drew their data from patients' regular clinical visits. [13,14] The studies were sufficiently current to analyze pemetrexed results after that agent's first-line approval for nonsquamous NSCLC.…”

Section: Introductionmentioning

confidence: 99%

Treatment patterns and cost-effectiveness of first line treatment of advanced non-squamous non-small cell lung cancer in Medicare patients

Gilden

Kubisiak

Pohl

et al. 2016

Journal of Medical Economics

View full text Add to dashboard Cite

show abstract

Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study

Cited by 62 publications

References 21 publications

Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study

Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study

Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions

Treatment patterns and cost-effectiveness of first line treatment of advanced non-squamous non-small cell lung cancer in Medicare patients

Contact Info

Product

Resources

About